Valuation: Omeros Corporation

Market Cap 1.32B 1.13B 1.06B 970M 1.83B 126B 1.84B 12.55B 4.88B 63.46B 4.95B 4.84B 210B P/E 2026 *
20.5x
P/E 2027 * 18.2x
Enterprise Value 1.32B 1.13B 1.06B 970M 1.83B 126B 1.84B 12.55B 4.88B 63.46B 4.95B 4.84B 210B EV / Sales 2026 *
10.5x
EV / Sales 2027 * 6.67x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day-5.50%
1 week+5.99%
Current month+53.89%
1 month+86.11%
3 months+58.99%
6 months+60.11%
Current year+6.08%
1 week 18.07
Extreme 18.07
19.65
1 month 10.5
Extreme 10.5
19.65
Current year 6.7
Extreme 6.7023
19.65
1 year 3.94
Extreme 3.94
19.65
3 years 0.92
Extreme 0.92
19.65
5 years 0.92
Extreme 0.92
19.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 16/06/1994
Director of Finance/CFO 62 30/06/2024
Chief Tech/Sci/R&D Officer 70 01/11/2019
Director TitleAgeSince
Chairman 67 16/06/1994
Director/Board Member 86 01/01/1995
Director/Board Member 72 01/01/1995
Date Insider Type Main position Quantity % Market Cap.
20/8/26 Fiscal year

Director

45,000 0.0622%
13/8/26 Fiscal year

Chief Financial Officer

15,000 0.0207%
12/8/26 Other

Director

528,082 0.7296%
Change 5-day change 1-year change 3-year change Capi.($)
-5.50%+5.99%+318.85%+378.22% 1.4B
+3.31%-3.70%+61.03%+103.64% 71.35B
+2.09%+3.17%+52.14%+91.30% 64.17B
-1.31%+21.36%+7.13%-4.29% 28.65B
+0.40%-3.17%-3.06%+469.55% 27.06B
-2.78%+4.47%+52.49%+14.43% 27.33B
-1.68%+2.61%+37.12%-16.09% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
-0.57%-4.06%+10.79%+515.61% 15.96B
-1.09%+5.61%+48.02%+155.12% 14.05B
Average -0.61%+5.23%+85.39%+212.78% 28.98B
Weighted average by Cap. +0.76%+3.36%+57.02%+155.20%

Financials

2026 *2027 *
Net sales 126M 108M 101M 92.38M 174M 11.98B 175M 1.2B 464M 6.04B 472M 461M 20B 198M 170M 159M 145M 274M 18.87B 276M 1.88B 731M 9.52B 743M 726M 31.5B
Net income 63.3M 54.31M 50.96M 46.56M 87.81M 6.04B 88.18M 603M 234M 3.05B 238M 232M 10.08B 79.47M 68.19M 63.97M 58.45M 110M 7.58B 111M 756M 294M 3.82B 298M 292M 12.66B
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
26/08/26 US$18.22 -5.50% 1,406,919
25/08/26 US$19.28 -0.21% 1,315,538
24/08/26 US$19.32 +0.26% 1,425,780
21/08/26 US$19.27 +3.44% 2,582,621
20/08/26 US$18.63 +1.31% 1,649,198
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
19.28USD
Average target price
33.00USD
Spread / Average Target
+71.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock